TOMSK, Sep 7 – RIA Tomsk. Scientists of Tomsk Polytechnic University (TPU) and Tomsk scientific
research institute of oncology plan to develop by 2020 radiopharmaceutical of
new generation for diagnostics and cancer therapy, the director of Institute of
Physics and Technology TPU Oleg Dolmatov told journalists.
Tandem of therapy and diagnostics
"In common we will realize tandem medicines which both diagnose,
and treat. Medicine will be marked not only with diagnostic isotope, but also
with isotope which bears therapeutic influence. There are no analogs of such
medicine in the world, but works are conducted by many collectives. In the
world this direction is called "theranostics" – therapy plus
diagnostics", – Dolmatov told.
He added that some experts call theranostics a panacea. "We won't
tell of such things loud yet. But we hope that we will make the
contribution", – the head of institute noted.
© с сайта Томского политехнического университета
According to him, works on radiopharmaceutical creation which are
conducted at the TPU research reactor, are planned to finish by 2020. Then the
stage of preclinical and clinical tests will begin.
Effective diagnostics
The director of Institute of Physics and Technology TPU reported that
now on the reactor there are about 30 various radiopharmaceuticals are
produced. It both prototypes for various tests, and the medicines allowed for
use. "Generally all of them are on the basis of technetium. These are
different diagnostic, therapeutic medicines", – he explained.
As it is reported on the website of the university, Polytechnic
University for the first time in world practice received at the reactor
nanocolloidal medicine on the basis of aluminum oxide, marked with
technetium-99 isotope. According to TPU, it is the first Russian medicine for
diagnostics of "sentry" lymph nodes. He is several times more
effective than foreign analogs.
"It is necessary for exact diagnosis of oncological diseases –
detection of the "sentry" lymph nodes (SLN). Through them take place
an outflow of a lymph from a tumor in an organism, or lymphogenous
metastasis", – is said on the website.
It is specified that medicine is necessary for not early stages of a
disease when the tumor was already created, the disease begun to extend on an
organism, and it is necessary to make the decision on treatment. Drug is
injected intravenously in an organism, substance collects in lymph nodes
through where a distribution of metastasis is happened. Lymph nodes can be
"examined", that is - to detect accurately.
"If you find SLN and conduct a histologic research, it is possible
to define unmistakably indications to carrying out the sparing operations. They
are carried out when tumor cells in "sentry" knots are not found. If
knots are struck with metastasises, then it is worth resorting to expanded
surgical intervention", – the press service reports.
"Unfortunately, now in Russia there is no registered medicine for
diagnostics of "sentry" lymph nodes though in the developed countries
such treatment – is the standard", – is added in the message.
In September will begin tests of a new radiopharmaceutical for the
diagnosis at the Tomsk scientific research institute of oncology.